Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: May-30-12
Credit Expiration Date: May-30-13

Faculty

William J. Sandborn, MD
Professor of Medicine
UC San Diego School of Medicine
Chief, Division of Gastroenterology
San Diego, CA

Scott Plevy, MD
Associate Professor of Medicine, Microbiology and Immunology
University of North Carolina School of Medicine
Chapel Hill, NC

Corey A. Siegel, MD
Director, Inflammatory Bowel Disease Center
Section of Gastroenterology and Hepatology
Dartmouth-Hitchcock Medical Center
Lebanon, NH



Credit Hours

0.5

Medium

Mobile + Online on RealCME

Program Description

A heterogeneous disease with varying levels of severity, Crohn’s Disease (CD) is a lifelong GI condition with substantial morbidity. Associated with debilitating symptoms, the ultimate treatment goal for CD is to modify the natural course of disease and achieve mucosal healing. However, treatment can be a challenging clinical problem, especially in patients with refractory disease. Persons with CD are likely to require hospitalization during the course of disease and have a high likelihood of requiring surgery. After achieving symptomatic remission, other treatment concerns include improved quality of life, induction and maintenance of remission, steroid-free remission, mucosal healing, and fewer surgeries and hospitalizations. New therapies and treatment strategies continue to be developed for patients with CD. Physicians will benefit from education on new concepts and strategies for the management of patients with CD.

Program Developer/Facilitator

This continuing medical education activity is jointly provided by the AGA Institute in collaboration with MCM Education.

Target Audience

Gastroenterologists and other health care providers interested in Crohn’s disease

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Assess disease severity and determine prognosis in patients with Crohn’s disease.
  2. Outline individual treatment goals for the different categories of Crohn’s disease.
  3. Summarize the risks and benefits of conventional and emerging treatment options for patients with moderate to severe Crohn’s disease.
  4. Develop optimal treatment approaches for Crohn’s disease based on individual patient prognosis.

Disclosures

The following authors have reported real or apparent conflicts of interest:

Activity Leader
William J. Sandborn, MD
Sources of Funding for Research: Abbott Laboratories, Bristol Meyers Squibb, Centocor (now Janssen), Genentech, Glaxo Smith Kline, Millennium Pharmaceuticals (now Takeda), Pfizer, Procter and Gamble Pharmaceuticals, Shire Pharmaceuticals, UCB
Consulting Agreements: Bristol Meyers Squibb, Genentech, Glaxo Smith Kline, Janssen (previously Centocor), Pfizer Inc.
Speakers' Bureau/Honorarium Agreements: Abbott Laboratories, Bristol Meyers Squibb, Janssen (previously Centocor)
Financial Interests/Stock Ownership: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Faculty
Scott Plevy, MD
Sources of Funding for Research: Prometheus Laboratories
Consulting Agreements: Biomodels, Inc., Drais Pharmaceuticals, Human Genome Sciences, NPS Pharmaceuticals, Prometheus Laboratories, Shire Pharmaceuticals, Therakos, Inc., TransTech Pharmaceuticals
Advisory Committees: Abbott Immunology, CalciMedica, Inc., enGene, Inc., Genentech, Inc., Janssen Biotech, Novartis, Novo Nordisk, Pfizer, Receptos, Synergy Pharmaceuticals, Takeda Pharmaceuticals, UCB
Speakers' Bureau/Honorarium Agreements: None
Financial Interests/Stock Ownership: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Faculty
Corey A. Siegel, MD
Sources of Funding for Research: Abbott Laboratories, Janssen Pharmaceuticals, Inc., UCB, Salix, Warner-Chilcott
Consulting Agreements: Abbott Laboratories, Janssen Pharmaceuticals, Inc., UCB, Elan, Prometheus Laboratories
Speakers' Bureau/Honorarium Agreements: None
Financial Interests/Stock Ownership: None
Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Planners and Reviewers Disclosure
Elizabeth Friedenwald, MCM Education medical writer, has no conflicts of interest to disclose.
Elizabeth Paczolt, MCM Education medical director, has no conflicts of interest to disclose.

Credit Statements

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The AGA Institute and RealCME. The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The AGA Institute designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

TERM OF OFFERING
This activity has a release date of May 30, 2012 and is valid for 1 year. Requests for credit must be received no later than May 30, 2013.

CREDIT DETERMINATION
A review committee has agreed that this material can be completed in 30 minutes. This estimated study time in turn has determined the credit hours being offered.

INSTRUCTIONS FOR PARTICIPATING IN THIS ACTIVITY AND OBTAINING CME CREDIT
There are no fees for participating in and receiving CME credit for this online educational activity. By reviewing the course content and successfully completing the posttest and evaluation, clinicians are entitled to receive credit. The statement of credit will be available to print from your user history page.
• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the posttest and activity evaluation
• Clinicians who successfully complete the posttest and evaluation will receive a CME certificate; successful completion is defined as a cumulative score of at least 80% correct
• All other participants who successfully complete the posttest and evaluation will receive a certificate of participation

Commercial Support Statements

This activity is supported by educational grants from Abbott Laboratories and UCB.

Certificate Fee

$0.00

Disclaimer

The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of The AGA Institute, MCM Education, or the commercial supporter(s). Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product, device, or procedure mentioned.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS